Hanmi Pharm. Co., Ltd.
Financials
Valuation Metrics
Hanmi Pharm. Co., Ltd.'s Market Cap is ₩6.8T. At end of 2025 it was ₩5.8T. Ranked #90 of 2,419 in KR market (top 4%), #85 of 781 on KOSPI (top 11%), #5 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.82T KRW | KR#90/2,419 Sec#5/231 |
| Revenue | 1.66T KRW | KR#294/2,419 Sec#9/231 |
| Net Income | 234.64B KRW | KR#127/2,419 Sec#4/231 |
| Total Assets | 2.33T KRW | KR#279/2,419 Sec#10/231 |
| Net Assets | 1.59T KRW | KR#212/2,419 Sec#8/231 |
| Employees | 2,388 | KR#123/2,419 Sec#3/231 |
| Value | ||
| P/E | 29.05x | KR#1,283/2,419 Sec#78/231 |
| P/B | 4.29x | KR#2,192/2,419 Sec#183/231 |
| PEG | 0.27x | KR#614/2,419 Sec#35/231 |
| P/S | 4.12x | KR#2,071/2,419 Sec#133/231 |
| EV/EBITDA | 21.71x | KR#1,042/2,419 Sec#62/231 |
| FCF Yield | 1.91% | KR#1,053/2,419 Sec#69/231 |
| Profitability | ||
| ROE | 14.77% | KR#334/2,419 Sec#23/231 |
| ROA | 10.05% | KR#273/2,419 Sec#21/231 |
| Op. Margin | 19.52% | KR#170/2,419 Sec#17/231 |
| Revenue Growth | 12.93% | KR#764/2,419 Sec#73/231 |
| Earnings Growth | 106.35% | KR#377/2,419 Sec#25/231 |
| Financial Health | ||
| Debt Ratio | 46.86% | KR#919/2,419 Sec#104/231 |
| Total Debt | 408.09B KRW | KR#348/2,419 Sec#14/231 |
| FCF | 130.05B KRW | KR#151/2,419 Sec#8/231 |
| Cash | 209.04B KRW | KR#259/2,419 Sec#9/231 |
| Current Ratio | 1.82x | KR#964/2,419 Sec#106/231 |
| Net Debt/EBITDA | 0.62x | KR#693/2,419 Sec#42/231 |
| Dividend | ||
| Div. Yield | 0.38% | KR#1,285/2,419 Sec#79/231 |
| Div. Growth | 60.00% | KR#201/2,419 Sec#7/231 |
| Performance | ||
| 1Y Return | 50.07% | KR#278/2,419 Sec#11/231 |
| 1M Return | 11.88% | KR#474/2,419 Sec#45/231 |
| From 52W High | -17.77% | KR#229/2,419 Sec#11/231 |
| 1Y MDD | -50.24% | KR#1,012/2,419 Sec#84/231 |
| Trading | ||
| Volume | 133,588 shares | KR#696/2,419 Sec#83/231 |
| Trading Value | 70.53B KRW | KR#56/2,419 Sec#3/231 |
| Foreign Own. | 13.74% | KR#351/2,419 Sec#23/231 |
| Per Share | ||
| EPS | 18,315 KRW | KR#56/2,419 Sec#3/231 |
| BPS | 124,041 KRW | KR#119/2,419 Sec#5/231 |
Company Info
Hanmi Pharmaceutical was established in 2010 through a spin-off of its pharmaceutical manufacturing and sales division, comprising three domestic and international subsidiaries. It produces Rosuzet, Amozaltan, and Esomezol, while Hanmi Fine Chemical exports cephalosporin-based antibiotics globally, and Beijing Hanmi Pharmaceutical Co., Ltd. sells various products. The company focuses on innovative new drug development, having acquired numerous patents by 2025, and is optimizing manufacturing processes and saving energy to reduce greenhouse gas emissions by 30% by 2030. Hanmi Pharmaceutical is headquartered in Hwaseong-si, Gyeonggi-do.